5 questions answered from cited research · Plain language
Fixed-duration subcutaneous mosunetuzumab shows a favorable safety profile with lower rates of severe immune-related adverse events compared to the intravenous version in relapsed follicular lymphoma.
Read the full answer →Adding R-CVP after radiotherapy significantly improves progression-free survival in early-stage follicular lymphoma, but overall survival benefit is not yet proven.
Read the full answer →Yes, new therapies like CAR T cells, bispecific antibodies, and targeted drugs show high response rates in follicular lymphoma patients who progress within 24 months.
Read the full answer →Abexinostat shows a 69.5% objective response rate in relapsed follicular lymphoma, based on a phase 2 trial.
Read the full answer →Yes, Revlimid (lenalidomide) is FDA-approved for previously treated follicular lymphoma, specifically in combination with rituximab.
Read the full answer →